• Nenhum resultado encontrado

Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.

N/A
N/A
Protected

Academic year: 2017

Share "Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia."

Copied!
11
0
0

Texto

Loading

Imagem

Table 1. Evaluation of hemostatic parameters and Incidence of bleeding events in patients with APL or de novo AML (other than APL).
Table 3. Compared analysis of hemostatic parameters between non-ATO group and ATO group.
Table 5. Compared analysis of consumption of component blood between non-ATO group and ATO group.
Table 6. Change in the trend of consumption of component blood in patients with APL with different prognostic stratification.

Referências

Documentos relacionados

the vast majority of CML patients, as well as in 30% of adult acute lymphoblastic leukemia (ALL) and 20% of childhood chromosome Ph positive ALL, the breakpoint in the BCR gene

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Liso V, Specchia G, Pogliani EM, Palumbo G, Mininni D, Rossi V,

Decitabine in the treatment of acute myeloide leukemia in elderly patients. Cancer

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and

Treatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies. Yoshii M, Ishida

Hybrid gene PML-RAR α is the molecular target found in most cases of acute promyelocytic leukemia (APL) and has been used for diagnosis and minimal residual disease

Tuberculosis showed peripheral enhancement, frequently with a multilocular appearance, in 43 (78.2%) patients, whereas patients with leukemia (78.9% for acute myeloid leukemia and

All-trans retinoic acid fol- low ed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in new ly diagnosed acute promyelocytic leukemia: a